Pirofski LA, Casadevall A. Pathogenesis of COVID-19 from the perspective of the damage-response framework. mBio. 2020;11(4):e01175–20. https://doi.org/10.1128/mBio.01175-20.

Balasko A, Keynan Y. Shedding light on IRIS: from pathophysiology to treatment of cryptococcal meningitis and immune reconstitution inflammatory syndrome in HIV-infected individuals. HIV Med. 2019;20(1):1–10.

Article  CAS  PubMed  Google Scholar 

Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with cryptococcosis according to immune status. PLoS One. 2013;8(3):e60431.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panackal AA, Wuest SC, Lin YC, Wu T, Zhang N, Kosa P, et al. Paradoxical immune responses in non-HIV cryptococcal meningitis. PLoS Pathog. 2015;11(5):e1004884.

Article  PubMed  PubMed Central  Google Scholar 

Anjum S, Dean O, Kosa P, Magone MT, King KA, Fitzgibbon E, et al. Outcomes in previously healthy cryptococcal meningoencephalitis patients treated with pulse taper corticosteroids for post-infectious inflammatory syndrome. Clin Infect Dis. 2021;73(9):e2789–e98.

Article  PubMed  Google Scholar 

Ssebambulidde K, Anjum SH, Hargarten JC, Chittiboina P, Shoham S, Seyedmousavi S, et al. Treatment recommendations for non-HIV associated cryptococcal meningoencephalitis including management of post-infectious inflammatory response syndrome. Front Neurol. 2022;13:994396.

Article  PubMed  PubMed Central  Google Scholar 

Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379(20):1915–25.

Article  CAS  PubMed  Google Scholar 

Wang X, Tang G, Liu Y, Zhang L, Chen B, Han Y, et al. The role of IL-6 in coronavirus, especially in COVID-19. Front Pharmacol. 2022;13:1033674.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E. A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther. 2018;5(1):21–42.

Article  PubMed  PubMed Central  Google Scholar 

Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N Engl J Med. 2021;384(16):1503–16.

Article  CAS  PubMed  Google Scholar 

Komori M, Blake A, Greenwood M, Lin YC, Kosa P, Ghazali D, et al. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann Neurol. 2015;78(1):3–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hommel B, Sturny-Leclere A, Volant S, Veluppillai N, Duchateau M, Yu CH, et al. Cryptococcus neoformans resists to drastic conditions by switching to viable but non-culturable cell phenotype. PLoS Pathog. 2019;15(7):e1007945.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albuquerque P, Nicola AM, Nieves E, Paes HC, Williamson PR, Silva-Pereira I, et al. Quorum sensing-mediated, cell density-dependent regulation of growth and virulence in Cryptococcus neoformans. mBio. 2013;5(1):e00986–13.

PubMed  PubMed Central  Google Scholar 

Schroder JB, Pawlowski M, Meyer Zu Horste G, Gross CC, Wiendl H, Meuth SG, et al. Immune cell activation in the cerebrospinal fluid of patients with Parkinson’s disease. Front Neurol. 2018;9:1081.

Article  PubMed  PubMed Central  Google Scholar 

Pharkjaksu S, Kwon-Chung KJ, Bennett JE, Ngamskulrungroj P. Population diversity and virulence characteristics of Cryptococcus neoformans/C. gattii species complexes isolated during the pre-HIV-pandemic era. PLoS Negl Trop Dis. 2020;14(10):e0008651.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol. 2013;190(8):3959–66.

Article  CAS  PubMed  Google Scholar 

Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology. 2004;126(4):989-96; discussion 947. https://doi.org/10.1053/j.gastro.2004.01.012.

Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011;585(23):3699–709.

Article  CAS  PubMed  Google Scholar 

Zinter MS, Hermiston ML. Calming the storm in HLH. Blood. 2019;134(2):103–4.

Article  CAS  PubMed  Google Scholar 

Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85–96.

Article  CAS  PubMed  Google Scholar 

Korn T, Hiltensperger M. Role of IL-6 in the commitment of T cell subsets. Cytokine. 2021;146:155654.

Article  CAS  PubMed  Google Scholar 

Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988;141(5):1543–9.

Article  CAS  PubMed  Google Scholar 

Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13(7):399–409.

Article  CAS  PubMed  Google Scholar 

Li Y, Zhao J, Yin Y, Li K, Zhang C, Zheng Y. The role of IL-6 in fibrotic diseases: molecular and cellular mechanisms. Int J Biol Sci. 2022;18(14):5405–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

She YX, Yu QY, Tang XX. Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov. 2021;7(1):52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Neal LM, Ganguly A, Kolbe JL, Hargarten JC, Elsegeiny W, et al. Chemokine receptor CXCR3 is required for lethal brain pathology but not pathogen clearance during cryptococcal meningoencephalitis. Sci Adv. 2020;6(25):eaba2502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panackal AA, Williamson KC, van de Beek D, Boulware DR, Williamson PR. Fighting the monster: applying the host damage framework to human central nervous system infections. mBio. 2016;7(1):e01906–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Edinoff AN, Alpaugh ES, Newgaard O, Wajid I, Klapper RJ, Cornett EM, et al. Tocilizumab for severe COVID-19 infection and multisystem inflammatory syndrome in adults and children. Life (Basel). 2023;13(4):889. https://doi.org/10.3390/life13040889.

Cheng PY, Sham A, Kronstad JW. Cryptococcus gattii isolates from the British Columbia cryptococcosis outbreak induce less protective inflammation in a murine model of infection than Cryptococcus neoformans. Infect Immun. 2009;77(10):4284–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang DH, England MR, Salvator H, Anjum S, Park YD, Marr KA, et al. Cryptococcus gattii species complex as an opportunistic pathogen: underlying medical conditions associated with the infection. mBio. 2021;12(5):e0270821.

Article  PubMed  Google Scholar 

Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291–322.

Article  PubMed  Google Scholar